Opinion|Videos|August 15, 2024
Managing Hematologic AEs Associated with ADC Treatments
A panel of experts discuss hematologic adverse events associated with antibody-drug conjugate therapies.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA approved gedatolisib/fulvestrant, with or without palbociclib, for hormone receptor–positive advanced breast cancer without a PIK3CA mutation.
The FDA approved selpercatinib for RET fusion–positive advanced solid tumors.
Read our recap of top phase 1 and 2 breast cancer data highlights that may lead to further clinical research and developments.
A triplet combination regimen led to high remission rates in patients with blastic plasmacytoid dendritic cell neoplasm.
The CDH17-targeting antibody-drug conjugate received the designation for previously treated advanced unresectable or metastatic colorectal cancer.
Read our recap of the top phase 3 breast cancer data announcements and highlights that may make waves in the future of breast cancer management.
The TRIPP-FFX trial met its primary end points of local disease control and safety with P-32 microparticles plus FOLFIRINOX pancreatic adenocarcinoma.
Ruxolitinib plus extracorporeal photopheresis drove responses in steroid-refractory or -dependent chronic graft-vs-host disease.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Gedatolisib Plus Fulvestrant ± Palbociclib for Hormone Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer
2
FDA Awards Traditional Approval to Selpercatinib for RET+ Advanced Solid Tumors
3
Research Rewind: Phase 3 Breast Cancer Data Highlights From Q2 2026
4
FDA Grants Fast Track Designation to SOT109 in Advanced Colorectal Cancer
5